“Advanced Ovarian Cancer Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Advanced Ovarian Cancer Market.
The Advanced Ovarian Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Advanced Ovarian Cancer Pipeline Report:
-
Companies across the globe are diligently working toward developing novel Advanced Ovarian Cancer treatment therapies with a considerable amount of success over the years.
-
Advanced Ovarian Cancer companies working in the treatment market are Daiichi Sankyo, Inc, Amgen, Compugen Ltd, NextCure, Sonnet BioTherapeutics, SOTIO Biotech B.V., Akeso, Allarity Therapeutics, Merck Sharp & Dohme, CanariaBio Inc., Allarity Therapeutics, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., and others, are developing therapies for the Advanced Ovarian Cancer treatment
-
Emerging Advanced Ovarian Cancer therapies in the different phases of clinical trials are- DS-6000a, AMG-794, COM701, NC762, SON-1010, SOT101, AK112, 2X-121, Pembrolizumab, Oregovomab, Stenoparib, DP-303c, and others are expected to have a significant impact on the Advanced Ovarian Cancer market in the coming years.
-
In September 2025, Allarity Therapeutics, Inc. (NASDAQ: ALLR), a Phase 2 clinical-stage biopharmaceutical company focused on developing stenoparib (2X-121)—a unique dual PARP and WNT pathway inhibitor—announced that Dr. Jeremy Graff, President and Chief Development Officer, presented new and updated clinical data from its ongoing Phase 2 trial in advanced ovarian cancer patients. The presentation took place at the AACR 7th Biennial Special Conference on Ovarian Cancer, held September 19–21, 2025, at the Grand Hyatt Denver, Colorado. The poster is available in the Scientific Publications section of the company’s website.
-
In September 2025, IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company advancing its DNA-mediated immunotherapy in Phase 3 development, announced new positive translational data from the Phase 2 OVATION 2 Study of IMNN-001. This investigational gene-based interleukin-12 (IL-12) immunotherapy, developed using the company’s proprietary TheraPlas® technology platform, is being evaluated for treating newly diagnosed advanced ovarian cancer. The findings were showcased in a presentation at the American Association for Cancer Research (AACR) Special Conference on Advances in Ovarian Cancer Research, held in Denver, Colorado.
-
In August 2025, According to a statement from Allarity Therapeutics, the U.S. FDA has granted Fast Track Designation to stenoparib, an investigational treatment for advanced ovarian cancer. This designation aims to expedite the development and review of therapies targeting serious conditions with significant unmet medical needs. It also allows for enhanced FDA interaction and may offer opportunities for accelerated approval, priority review, or rolling submissions if certain requirements are met.
-
In April 2025, Corcept Therapeutics announced that its pivotal Phase III ROSELLA trial evaluating oral relacorilant in combination with nab-paclitaxel met its primary endpoint by demonstrating improved progression-free survival (PFS) in patients with platinum-resistant ovarian cancer. The study, which enrolled 381 patients across Argentina, Brazil, Canada, Europe, Australia, and South Korea, showed that the combination therapy reduced the risk of disease progression by 30% compared to treatment with nab-paclitaxel alone.
-
In March 2025, Imunon announced that the U.S. Food and Drug Administration (FDA) has agreed on the Phase III OVATION 3 trial protocol for IMNN-001 in ovarian cancer. IMNN-001, the company’s lead investigational therapy, is being developed for women newly diagnosed with advanced ovarian cancer. The company is now initiating clinical trial sites and collaborating with investigators to begin patient enrollment.
-
In March 2025, AbbVie, a U.S.-based pharmaceutical company, announced the final results from its Phase III MIRASOL trial evaluating the antibody-drug conjugate (ADC) Elahere against chemotherapy in patients with platinum-resistant ovarian cancer (PROC). This randomized study assessed the safety and efficacy of Elahere in women with folate receptor alpha (FRα)-positive PROC.
-
In November 2024, IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company advancing its DNA-mediated immunotherapy, has announced new clinical data from the recently completed Phase 2 OVATION 2 Study of IMNN-001, an investigational interleukin-12 (IL-12) immunotherapy for advanced ovarian cancer developed using its proprietary TheraPlas® technology. The findings will be showcased in a late-breaking poster session at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting.
-
In August 2024, South Korean biopharmaceutical firm CanariaBio completed subject enrollment for its Phase II clinical trial evaluating oregovomab in combination with chemotherapy for advanced epithelial ovarian cancer. Known as FLORA-6, this double-blinded, placebo-controlled, multicenter study aims to assess the effectiveness of oregovomab alongside chemotherapy agents paclitaxel and carboplatin as a neo-adjuvant treatment for newly diagnosed patients.
-
In October 2024, Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company advancing a pipeline of innovative multifunctional biotherapeutics for challenging diseases, has announced the dosing of the first patient in its first-in-human Phase 1 trial (NCT06523803). This study aims to assess the safety and tolerability of the investigational therapy ZW171 for the treatment of advanced or metastatic ovarian cancer, non-small cell lung cancer (NSCLC), and other MSLN-expressing cancers
-
In May 2024, EVT801, a highly selective small-molecule VEGFR3 TKI, demonstrated good tolerability in patients with advanced solid tumors, with a 46% stable disease rate observed in advanced ovarian cancer patients, as reported in a Phase 1 trial (NCT05114668).
Advanced Ovarian Cancer Overview
Advanced ovarian cancer refers to ovarian cancer that has spread beyond the ovaries to other parts of the pelvis, abdomen, or distant organs. It is typically classified as Stage III or IV, depending on the extent of spread. Symptoms may be vague, such as bloating, abdominal pain, early satiety, or urinary changes, which often leads to late diagnosis. Treatment usually involves a combination of surgery to remove as much of the tumor as possible (debulking) and chemotherapy, sometimes alongside targeted therapies or immunotherapy. Prognosis depends on factors like stage at diagnosis, tumor type, and response to treatment.
Get a Free Sample PDF Report to know more about Advanced Ovarian Cancer Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/advanced-ovarian-cancer-pipeline-insight
Emerging Advanced Ovarian Cancer Drugs Under Different Phases of Clinical Development Include:
-
DS-6000a: Daiichi Sankyo, Inc
-
AMG-794: Amgen
-
COM701: Compugen Ltd
-
NC762: NextCure
-
SON-1010: Sonnet BioTherapeutics
-
SOT101: SOTIO Biotech B.V.
-
AK112: Akeso
-
2X-121: Allarity Therapeutics
-
Pembrolizumab: Merck Sharp & Dohme
-
Oregovomab: CanariaBio Inc.
-
Stenoparib: Allarity Therapeutics
-
DP-303c: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Advanced Ovarian Cancer Route of Administration
Advanced Ovarian Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
-
Oral
-
Parenteral
-
Intravenous
-
Subcutaneous
-
Topical.
Advanced Ovarian Cancer Molecule Type
Advanced Ovarian Cancer Products have been categorized under various Molecule types, such as
-
Monoclonal Antibody
-
Peptides
-
Polymer
-
Small molecule
-
Gene therapy
Advanced Ovarian Cancer Pipeline Therapeutics Assessment
-
Advanced Ovarian Cancer Assessment by Product Type
-
Advanced Ovarian Cancer By Stage and Product Type
-
Advanced Ovarian Cancer Assessment by Route of Administration
-
Advanced Ovarian Cancer By Stage and Route of Administration
-
Advanced Ovarian Cancer Assessment by Molecule Type
-
Advanced Ovarian Cancer by Stage and Molecule Type
DelveInsight's Advanced Ovarian Cancer Report covers around 50+ products under different phases of clinical development like
-
Late-stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I)
-
Pre-clinical and Discovery stage candidates
-
Discontinued & Inactive candidates
-
Route of Administration
Further Advanced Ovarian Cancer product details are provided in the report. Download the Advanced Ovarian Cancer pipeline report to learn more about the emerging Advanced Ovarian Cancer therapies
Some of the key companies in the Advanced Ovarian Cancer Therapeutics Market include:
Key companies developing therapies for Advanced Ovarian Cancer are - Pfizer, Daiichi Sankyo, Inc., Astellas Pharma Inc, Jiangsu HengRui Medicine Co., Ltd., Boehringer Ingelheim, Impact Therapeutics, Inc., Glycotope, ImmunoGen, OncoQuest, Lee's Pharmaceutical, Allarity Therapeutics, AstraZeneca, Jiangxi Qingfeng Pharmaceutical Co. Ltd., Bayer, Xennials Therapeutics, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Ellipses Pharma, Merck KGaA, Puma Biotechnology, Inc., MaxCyte, Inc., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., and others.
Advanced Ovarian Cancer Pipeline Analysis:
The Advanced Ovarian Cancer pipeline report provides insights into
-
The report provides detailed insights about companies that are developing therapies for the treatment of Advanced Ovarian Cancer with aggregate therapies developed by each company for the same.
-
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Advanced Ovarian Cancer Treatment.
-
Advanced Ovarian Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
Advanced Ovarian Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Advanced Ovarian Cancer market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Advanced Ovarian Cancer drugs and therapies
Advanced Ovarian Cancer Pipeline Market Drivers
-
Increasing prevalence of Advanced Ovarian Cancer, increasing research and development activities, launch of novel drugs are some of the important factors that are fueling the Advanced Ovarian Cancer Market.
Advanced Ovarian Cancer Pipeline Market Barriers
-
However, huge expenditure of the treatment methods, adverse effects associated with the drugs and other factors are creating obstacles in the Advanced Ovarian Cancer Market growth.
Scope of Advanced Ovarian Cancer Pipeline Drug Insight
-
Coverage: Global
-
Key Advanced Ovarian Cancer Companies: Daiichi Sankyo, Inc, Amgen, Compugen Ltd, NextCure, Sonnet BioTherapeutics, SOTIO Biotech B.V., Akeso, Allarity Therapeutics, Merck Sharp & Dohme, CanariaBio Inc., Allarity Therapeutics, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., and others
-
Key Advanced Ovarian Cancer Therapies: DS-6000a, AMG-794, COM701, NC762, SON-1010, SOT101, AK112, 2X-121, Pembrolizumab, Oregovomab, Stenoparib, DP-303c, and others
-
Advanced Ovarian Cancer Therapeutic Assessment: Advanced Ovarian Cancer current marketed and Advanced Ovarian Cancer emerging therapies
-
Advanced Ovarian Cancer Market Dynamics: Advanced Ovarian Cancer market drivers and Advanced Ovarian Cancer market barriers
Request for Sample PDF Report for Advanced Ovarian Cancer Pipeline Assessment and clinical trials
Table of Contents
1. Advanced Ovarian Cancer Report Introduction
2. Advanced Ovarian Cancer Executive Summary
3. Advanced Ovarian Cancer Overview
4. Advanced Ovarian Cancer- Analytical Perspective In-depth Commercial Assessment
5. Advanced Ovarian Cancer Pipeline Therapeutics
6. Advanced Ovarian Cancer Late Stage Products (Phase II/III)
7. Advanced Ovarian Cancer Mid Stage Products (Phase II)
8. Advanced Ovarian Cancer Early Stage Products (Phase I)
9. Advanced Ovarian Cancer Preclinical Stage Products
10. Advanced Ovarian Cancer Therapeutics Assessment
11. Advanced Ovarian Cancer Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Advanced Ovarian Cancer Key Companies
14. Advanced Ovarian Cancer Key Products
15. Advanced Ovarian Cancer Unmet Needs
16 . Advanced Ovarian Cancer Market Drivers and Barriers
17. Advanced Ovarian Cancer Future Perspectives and Conclusion
18. Advanced Ovarian Cancer Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/
